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Abstract: The increasing incidence and high morbidity and mortality of hepatocellular carci-
noma (HCC) have inspired the creation of the Liver Imaging Reporting and Data System (LI-
RADS). LI-RADS aims to reduce variability in exam interpretation, improve communication, 
facilitate clinical therapeutic decisions, reduce omission of pertinent information, and facilitate 
the monitoring of outcomes. LI-RADS is a dynamic process, which is updated frequently. In 
this article, we describe the LI-RADS 2014 version (v2014), which marks the second update 
since the initial version in 2011.
Keywords: hepatocellular carcinoma, imaging,  reporting, cirrhosis, hyperenhancement washout
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common tumor and the second 
most common cause of cancer-related death worldwide.1 The incidence of HCC in the 
US has tripled over the last three decades,2 which has been attributed largely to the 
epidemic of chronic hepatitis C virus (HCV) infection acquired through intravenous 
drug use and blood transfusions between 1960 and 1980.2–4 HCV infection accounts 
for the increasing incidence of HCC in developed countries and has become the single 
most frequent cause of HCC,5 although HCV is associated with only one-third of HCC 
cases in developing countries. Thus, hepatitis B virus (HBV) infection still accounts 
for more than half of the world’s overall HCC burden, although its incidence is now 
decreasing because of increasing worldwide vaccination.2
The most consistent predisposing factor in the development of HCC is cirrhosis, 
as 80% of HCC cases develop in the cirrhotic liver.6 In addition to HCV and HBV 
infections, other causes of cirrhosis include hereditary hemochromatosis, alcoholic 
cirrhosis, biliary cirrhosis, and now increasingly, nonalcoholic steatohepatitis (NASH) 
related to the rising incidence of obesity, diabetes, and metabolic syndrome.7 It has 
also been suggested that most cases of cryptogenic cirrhosis represent the end stages 
of nonalcoholic fatty liver disease in which the liver has progressed to a markedly 
fibrotic state devoid of fat.8 In contrast to other causes of cirrhosis, 30% of patients 
with chronic HBV infection develop HCC without cirrhosis.9,10
The significant morbidity and mortality associated with HCC makes early detection 
and diagnosis critical. Serum alpha-fetoprotein (AFP) measurements and ultrasound 
have been associated with greater mortality reduction than other screening methods, 
although their sensitivity is only 50–60% individually.11,12 Contrast-enhanced magnetic 
resonance imaging (MRI) and computed tomography (CT) are the two most widely used 
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imaging techniques for diagnosis of HCC following initial 
detection by surveillance AFP or ultrasound, with per-lesion 
sensitivities of 83% and 76% and per-lesion specificities of 
87% and 89%, respectively.13 As important advancements 
in imaging technology have evolved, imaging has played 
an increasingly important role in HCC evaluation, so that 
pretreatment biopsy is not currently mandated by most cur-
rent clinical practice guidelines in a patient at risk for HCC 
when appropriate imaging demonstrates the typical features 
of HCC.14 At the other extreme, incorrect diagnosis can 
adversely affect management if a false-negative diagnosis 
leads to delayed detection until advanced stages or if false-
positive diagnoses may lead to unnecessary surgery or treat-
ment. The detection of small tumors and the management of 
small hypervascular nodules remain important challenges in 
imaging diagnosis and evaluation of HCC.15
With imaging occupying a central role in diagnosis, stag-
ing, and management decisions, the need for a consistent 
lexicon and well-defined diagnostic criteria has never been 
greater. To address this need and to improve clarity and 
quality in diagnostic reports, the Liver Imaging Reporting 
and Data System (LI-RADS), a consensus American Col-
lege of Radiology (ACR)-supported initiative analogous to 
BI-RADS in breast imaging, was created.16 LI-RADS aims 
to reduce variability in exam interpretation, improve com-
munication, facilitate clinical therapeutic decisions, reduce 
omission of pertinent information, and facilitate the monitor-
ing of outcomes.16
LI-RADS was created by radiologists collaborating with 
other liver specialists, for all radiologists to use, in both 
academic and community or private practice settings. LI-
RADS is updated continuously, incorporating improvements 
in imaging techniques. The LI-RADS 2014 version (v2014), 
described in this article, marks the second update since the 
initial version was released by the ACR in 2011, offering sev-
eral enhancements to the previous version (Table 1).17 These 
refinements are discussed in later sections of this article. As 
part of LI-RADS, there is an Evidence Based Workgroup 
that regularly reviews new publications and information in 
the literature and helps to guide future versions of LI-RADS. 
A 2017 update is planned with further refinements, improve-
ments, and updates; some of these future expanded roles of 
LI-RADS v2017 will be discussed later.
LI-RADS: overview
LI-RADS is a system created for the standardized inter-
pretation and reporting of liver imaging examinations in 
patients at risk for HCC. This system was developed with 
the  cooperative and ongoing efforts of an ACR-supported 
committee composed of diagnostic radiologists with expertise 
in liver imaging, with valuable input from hepatobiliary sur-
geons, hepatologists, hepatopathologists, and interventional 
radiologists. The goal of LI-RADS is to provide standard 
terminology and diagnostic criteria to help readers assign 
categories (from 1 through 5), which reflect the probability 
of benignity or malignancy in patients at risk for HCC.17 
LI-RADS also provides recommendations regarding tech-
nical requirements of contrast-enhanced CT and MRI. As 
part of the LI-RADS mission, this system provides on the 
ACR website a lexicon of imaging features illustrated by 
schematics and an atlas lexicon of terminology to allow 
standardized language to be used in radiology reports. v2014 
included a standardized downloadable reporting template to 
help radiologists include all pertinent findings and follow the 
LI-RADS terminology and approach.
Classification within the LI-RADS system is dependent 
on distinct imaging features, which increase or decrease the 
probability of HCC to various degrees, using an algorithmic 
approach.16 This begins by noting whether any distinctive 
focal alteration within liver parenchyma is present, referred 
to as an observation, because not all of these are masses. The 
process by which liver observations are classified is demon-
strated in the algorithm in Figure 1.17 Unlike the previous 
version, v2014 includes a distinct category for previously 
treated observations.17 Of note, imaging criteria in v2014 
applies to CT or MRI with the use of extracellular contrast 
agents and also includes material on the interpretation of MRI 
performed with hepatobiliary contrast agents.
Similar to LI-RADS for CT and MRI, CEUS LI-RADS 
was more recently developed as a standardizing system for 
technique, interpretation, reporting, and data collection of 
contrast-enhanced ultrasound in patients at risk for develop-
ing HCC.17 Another impressive collaboration of national and 
international radiology and hepatology experts, the CEUS 
LI-RADS algorithm was first released in June 2016, shortly 
after US Food and Drug Administration approval of the use 
of ultrasound contrast.17 With the development of CEUS 
LI-RADS guidelines, contrast-enhanced ultrasound provides 
another modality with which HCC can be diagnosed, charac-
terized, and treated sooner and more efficiently, without the 
need for pretreatment biopsy. Although contrast-enhanced 
ultrasound is not within the scope of this article, we feel it 
is important to note that, like LI-RADS for CT and MRI, 
CEUS LI-RADS is a dynamic process which is scheduled for 
updates in 2017, and 2020, and serves as a valuable resource 
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Liver Imaging Reporting and Data System
LI-RADS algorithm
The LI-RADS algorithm is utilized from top to bottom and 
left to right. Treated observations – according to clinical 
history – are assigned to the LI-RADS-treated category. 
Untreated observations may be assigned to the following 
categories: LR-1 for definitely benign, LR-2 for probably 
benign, LR-M for probable malignancy not specific for HCC, 
and LR-5V for HCC with tumor in vein. Observations that 
do not fit in any of the previous categories will be assigned 
to one of the following categories: LR-3 for intermediate 
probability of HCC, LR-4 for probable HCC, or LR-5 for 
definite HCC depending on the combination of major imag-
ing features discussed subsequently (Table 2).17
Major imaging features
In v2014, LI-RADS uses five major imaging features to 
establish the diagnosis of HCC. These include arterial-phase 
hyperenhancement, diameter, washout appearance, capsule 
appearance, and threshold growth.17
v2014 no longer requires formal identification of a mass, 
which was previously defined as a three-dimensional space-
occupying lesion that displaces or replaces underlying hepatic 
parenchyma.16
Arterial-phase hyperenhancement
Arterial-phase hyperenhancement, a major feature of HCC 
diagnosis, reflects the increased arterial vascularization that 
Table 1 Comparison between LI-RADS v2011 and v2014
Category LI-RADS v2011 LI-RADS v2014
LR treated No LR-treated category Any observation that has undergone locoregional treatment, 
regardless of the outcome




<20 mm arterial-phase iso- or hypoenhancing mass 
with ≤1 of the following: portal/delayed phase 
hypoenhancement, diameter increase by ≥10 mm in 1 year
<20 mm arterial hyperenhancing mass with neither portal/
delayed phase hypoenhancement nor ≥10 mm diameter 
increase within 1 year, or <20 mm arterial hyperenhancing 
nonmass-like and stable
≥20 mm iso- or hypoenhancing mass with neither portal/
delayed phase hypoenhancement nor ≥10 mm diameter 
increase within 1 year, or ≥20 mm arterial hyperenhancing 
nonmass-like and stable
<20 mm arterial-phase iso- or hypoenhancing with “washout” 
only or “capsule” only or threshold growth only or none
≥20 mm arterial-phase iso- or hypoenhancing without 
“washout,” “capsule,” or threshold growth
<20 mm arterial-phase hyperenhancing without “washout,” 




<20 mm arterial iso- or hypoenhancing mass with both 
portal/delayed phase hypoenhancement and ≥10 mm 
diameter increase within 1 year
<20 mm arterial-phase hyperenhancing mass with either 
portal/delayed phase hypoenhancement or ≥10 mm 
diameter increase within 1 year, but not both
LR-4B
≥20 mm arterial-phase iso- or hypoenhancing mass with 
portal/delayed phase hypoenhancement or ≥10 mm 
diameter increase within 1 year or both
≥20 mm arterial-phase hyperenhancing mass with neither 
portal/delayed phase hypoenhancement nor ≥10 mm 
diameter increase within 1 year
No A or B distinction
<20 mm arterial-phase iso- or hypoenhancing with ≥2 of the 
following: “washout,” “capsule,” or threshold growth
<10 mm arterial-phase hyperenhancing with ≥1 of the 
following: “washout,” “capsule,” or threshold growth
10–19 mm arterial-phase hyperenhancing with “washout” only 
or “capsule” only or threshold growth only
≥20 mm arterial-phase iso- or hypoenhancing with ≥1 of the 
following: “washout,” “capsule,” or threshold growth
≥20 mm arterial hyperenhancing mass without “washout”, 




≥10 and <20 mm arterial hyperenhancing mass with both 
portal/delayed phase hypoenhancement and ≥ 10 mm 
diameter increase within 1 year
LR-5B
≥20 mm arterial hyperenhancing mass with portal/delayed 
phase hypoenhancement or ≥10 mm diameter within 
1 year or both
No A or B distinction
10–19 mm arterial-phase hyperenhancing with ≥2 of the 
following: “washout,” “capsule,” or threshold growth
≥20 mm arterial hyperenhancing with ≥1 of: “washout,” 
“capsule,” or threshold growth
LR-5V No LR-5V category Mass with definite tumor in vein
LR-M No LR-M category Features suggestive of non-HCC malignancy such as rim arterial-
phase hyperenhancement or peripheral washout appearance
Notes: See Table 2 for LI-RADS classifications.
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HCC).17 All or part of the observation in question must 
demonstrate greater enhancement, and have higher signal 
intensity, than the surrounding liver during the arterial phase 
(Figure 2).20,21 The late arterial phase is preferred over the 
early arterial phase to demonstrate this major feature.
Arterial-phase hypoenhancement or isoenhancement refers 
to enhancement of an observation that is less than or equal 
to that of the liver during the arterial phase.16 This feature 
does not include nonenhancing observations.17 If definitive 
discrimination between hyperenhancement and iso- or hypoen-
hancement cannot be made, then this cannot be considered 
hyperenhancement. After evaluating the presence or absence 
of hyperenhancement, other major features – observation 
diameter, washout appearance, capsule appearance and thresh-
















Observations in this cell are categorized LR-4 except as follows:
LR-5g, if there is ≥ 50% diameter increase in ≤ 6 months. These observations are equivalent to OPTN 5A-g.





















Observation in high-risk patient









Figure 1 LI-RADS v2014 algorithm.
Notes: See Table 2 for LI-RADS classifications. Copyright ©2016. Dove Medical Press. Reproduced from American College of Radiology. Liver Imaging and Reporting System 
version 2014. Available from: https://nrdr.acr.org/lirads/.17
Abbreviations: LI-RADS, Liver Imaging Reporting and Data System; HCC, hepatocellular carcinoma; OPTN, Organ Procurement and Transplantation Network; AASLD, 
American Association for the Study of Liver Diseases.




LR-3 Intermediate probability of HCC
LR-4 High probability of HCC, not 100%
LR-5 Definitely HCC
LR-5V Definite venous invasion regardless of other 
imaging features
LR treated LR-5 lesion status post-locoregional treatment
LR-M Non-HCC malignancies that may occur in cirrhosis: 
metastases, lymphoma, cholangiocarcinoma, PTLD
Abbreviations: LI-RADS, Liver Imaging Reporting and Data System; HCC, 
hepatocellular carcinoma; PTLD, post-transplant lymphoproliferative disorder.
occurs at the expense of portal venous supply during hepa-
tocarcinogenesis.18–20 Only observations with arterial-phase 
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Liver Imaging Reporting and Data System
Observations without definite hyperenhancement may be 
ultimately categorized as LR-3 or LR-4, but not as LR-5.17
Diameter
Diameter is defined as the largest diameter (outer edge to outer 
edge) measured in the sequence or phase in which the margins 
are most sharply demarcated and without apparent anatomic 
distortion.17 It is preferable to avoid measuring an observation 
in the arterial phase, as measurement in this phase is less reli-
able if the enhancement is incomplete due to an early arterial 
phase or if there is perilesional enhancement. Diameter, as a 
major imaging feature, is stratified into four size categories:
Diameter <20 mm is used to further categorize masses 
with arterial-phase hypo- or isoenhancement. Masses that 
meet both of these criteria can be categorized as LR-3 or 
LR-4, depending upon other imaging features. They cannot, 
however, be categorized at LR-5.17
Diameter <10 mm is used to further characterize masses 
with arterial-phase hyperenhancement. Masses that meet both 
of these criteria may be categorized as LR-3 or LR-4, depend-
ing upon the presence of other major or ancillary imaging 
features.16,17 These observations cannot be categorized as 
definite HCC (LR-5) because of the lower specificity of CT 
or MRI for nodules <1 cm.17
Diameter 10–19 mm is used to further categorize masses 
with arterial-phase hyperenhancement. Masses that meet 
both of these criteria may be categorized as LR-4 or LR-5, 
depending upon the presence of other major or ancillary 
imaging features.17 Two or more additional major features 
are required for these observations to reach LR-5. To be 
congruent with the American Association for the Study of 
Liver Diseases (AASLD) and United Network for Organ 
Sharing (UNOS)-Organ Procurement and Transplantation 
Network (OPTN) practice guidelines,22,23 observations that 
present both washout appearance and visibility at anteced-
ent surveillance ultrasound (LR-5us) and observations that 
present ≥50% diameter increase in ≤6 months (LR-5g) can 
also be assigned an LR-5 category.
Diameter ≥20 mm is used to further characterize masses 
with any type of arterial-phase enhancement. These masses 
may be categorized as LR-3, LR-4, or LR-5, depending upon 
other major or ancillary imaging features.17
Washout appearance
Washout appearance, as it is called in the two most recent 
versions of LI-RADS (v2013 and v2014), was previously 
known as “portal venous or later-phase hypoenhancement” 
in the 2011 version. This terminology is congruent with 
OPTN terminology.17 The term “washout appearance” is used 
because not all of these observations have true washout, as 
defined by reducing signal on enhancement curves; increased 
enhancement of background liver can contribute to wash-
out appearance. Washout appearance is a strong predictor 
of HCC in arterially hyperenhancing hepatic observations 
(Figure 2).24This phenomenon results from decreased portal 
venous supply to, and early venous drainage from, the HCC 
accompanying neoangiogenesis, in addition to increased late 
enhancement of fibrosis in the surrounding liver parenchyma 
during portal venous or delayed phases following extracellular 
contrast agent administration.25,26 Special care should be made 
to ensure that the degree of enhancement during these phases 
is unequivocally lower than during earlier phases, as well as 
making certain that the same observations are compared in 
different phases.27 Subtraction imaging may be helpful to 
assess washout. Rimola et al28 evaluated washout features with 
dynamic MRI in 5–20 mm observations detected by screening 
ultrasound of patients with cirrhosis. Though the sensitivity of 
washout was only 58.3%, diagnosis of HCC in masses dem-
onstrating arterial hyperenhancement with washout yielded 
specificity of 96.4% and a positive predictive value of 96.8%.28 
How well these results generalize to observations that were not 
first detected by screening ultrasound is not well understood.
Figure 2 HCC in a 57-year-old man with chronic HCV.
Notes: Axial post-contrast T1-weighted MR images in arterial (A) and delayed phase (B) demonstrate a well-circumscribed oval lesion measuring 2.5 cm in maximal 
dimension exhibiting homogeneous hyperenhancement in the arterial phase (arrow) with washout and enhancing capsule in the delayed phase (arrow). This lesion is category 
LR-5. See Table 2 for LI-RADS classifications.
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Washout can be present as only part of an observation, 
which presents a potential pitfall. Washout in the periphery 
of an observation is considered “peripheral washout” and 
not “washout appearance.” Peripheral washout suggests 
intrahepatic cholangiocarcinoma rather than HCC, making 
an observation fall into the LR-M category.17
Fibrosis may also create the false perception of washout. 
Fibrosis generally demonstrates increased enhancement on 
late post-contrast images, potentially creating an appearance 
of hypoenhancement of an encompassed regenerative nodule 
or mimicking a delayed enhancing capsule.16,29
Capsule appearance
Capsule appearance is a major feature of HCC defined as 
a peripheral rim of smooth hyperenhancement in the portal 
venous or delayed phase that unequivocally is thicker and more 
conspicuous than the rims surrounding background nodules 
(Figure 2).28 Since some of these masses may not have a true 
capsule, the terms capsule appearance or “capsule” (with quotes) 
are preferred over capsule alone. Whether a mass has a true cap-
sule or pseudocapsule can only be distinguished pathologically, 
and there are no data to support the diagnostic significance of 
this distinction. The degree of enhancement typically increases 
between the portal venous and delayed venous phases. Rimola 
et al28 found that capsule appearance provided a sensitivity, 
specificity, negative predictive value, and positive predictive 
value of 41.7%, 96.4%, 95.6%, and 47.4%, respectively.
Threshold growth
Threshold growth is a major feature that reflects shorter 
tumor volume doubling time of HCC compared to that of 
nonmalignant lesions.16 Threshold growth is defined as a 
diameter increase of a mass by at least 5 mm and by a >50% 
increase in ≤6 months, or >100% in >6 months. A new mass 
≥10 mm in size, regardless of time interval, is also consid-
ered as threshold growth.16 Of note, masses that demonstrate 
threshold growth but do not demonstrate arterial-phase 
hyperenhancement may not be categorized as LR-5.17 It is 
important to measure consistently in the same plane and, if 
possible, in the same sequence or phase. Again, the arterial 
phase is not ideal for measurement, as these measurements 
may be affected by the early timing of the image acquisition 
or perilesional enhancement.17
Tumor in vein
Vascular invasion of HCC occurs by direct invasion of the 
tumor into an adjacent portal, or less often, hepatic vein.30,31 
Tumor in a vein, defined as definitive soft tissue enhancement 
within a vein, is now the preferred term over tumor thrombus.16 
This feature – which is associated with a poor prognosis, modi-
fies the staging, and may contraindicate eligibility for local 
ablative therapies and liver transplantation – is demonstrated 
by unequivocal luminal enhancement in the arterial phase with 
washout of the soft tissue component of the tumor.32 Tumors 
demonstrating this feature are classified as LR-5V, a definitive 
diagnosis of HCC (although indeed some cholangiocarcino-
mas show tumor extension into veins).17
Mimics of venous involvement include early enhance-
ment of the portal veins related to late arterial-phase tim-
ing, the presence of arterioportal shunting, or hepatofugal 
flow.14 Similar findings in the hepatic veins can occur with 
arteriovenous shunting or reflux of contrast into the hepatic 
veins from the inferior vena cava.16 Thus, observation of 
washout after enhancement in the involved vein, greater than 
other vessels, is critical. In general, tumor in the vein will 
demonstrate a more heterogeneous appearance than shunted/
retrograde contrast flow (Figure 3). Another mimic of tumor 
thrombus is bland (chronic) thrombus, which also occurs 
in cirrhosis secondary to portal hypertension and venous 
stasis.31 In comparison to tumor in the vein, bland thrombus 
causes less expansion of the vessels, does not demonstrate 
contrast enhancement, and may exhibit low T2 signal related 
to hemosiderin when it is long standing.16,33 Cavernous trans-
formation around a bland thrombus can serve as an additional 
complicating factor.16 Doppler ultrasound or tissue sampling 
may be helpful in determining the nature of a thrombus when 
tumor in vein versus bland thrombus are questioned.
Ancillary imaging features
Ancillary features, which can be used to upgrade or downgrade 
an observation by one or more categories, are left to the discre-
tion of the radiologist.16 These features modify the likelihood 
of HCC but are currently not supported by sufficient evidence 
to categorize a finding independently.17 Ancillary features that 
favor HCC may be used to upgrade observations from one LI-
RADS category to the next, but such upgrades may go only as 
high as LR-4 and not to LR-5. Similarly, imaging features that 
favor benignity may be used to downgrade observations that 
otherwise meet major criteria for a higher category.16 Absence 
of ancillary features does not justify designation of a higher 
or lower category.17 Examples of ancillary features favoring 
HCC or benignity are listed in Table 3.
If, after application of ancillary features, a radiologist 
is still unsure about the final category for an observation, 
tiebreaking rules should be applied. Generally, tiebreaking 
rules move observations away from LR-1 and LR-5 toward 
LR-3 to maintain the highest degree of specificity for the 
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Liver Imaging Reporting and Data System
v2014 categories
LI-RADS categories, with corresponding descriptions and 
management guidance, are summarized in Table 2.
Category LR-1
Observations in this category are definitely benign, with 100% 
certainty.17 Unnecessary follow-up imaging may be avoided, 
and multidisciplinary discussion is not warranted.17 Lesions 
in LR-1 and LR-2 categories are summarized in Table 4.
Category LR-2
Findings in this category have a high probability, though not 
100%, of being benign. Most of these are benign processes 
with an atypical appearance, such as slow-filling heman-
giomas.17 Notably, focal perfusion alterations related to 
nonmalignant arterioportal shunts or portal venous branch 
obstruction are LR-2 observations, because small HCCs may 
occasionally have similar appearance.11,34 Imaging charac-
teristics include peripheral, wedge-shaped, and exclusively 
arterial-enhancing observations that are isointense or near 
isointense on T1- and T2-weighted images.35 If not all of 
these criteria are met, the observation should be considered 
LR-3 or LR-4.36 Particular caution is indicated here because 
perfusion alteration can occur secondary to focal hepatic 
observations, such as HCC.34
Some other examples of LR-2 observations are vascular 
anomalies, perfusion alterations, hepatic fat deposition or 
sparing and focal scars, among others. Hepatic adenoma and 
focal nodular hyperplasia (FNH) are generally not considered 
Table 3 Ancillary imaging features in favoring diagnosis of HCC 
and favoring benignity
Favor HCC Favor benignity
Mild to moderate T2 hyperintensity Uniform marked T2 hyperintensity
Subthreshold growth Uniform marked T2 hypointensity
Mosaic architecture Normal, undistorted vessels 
crossing through region of interest 
Fat deposition disproportionate to 
that in the surrounding fat
Blood pool enhancement 
characteristics
Restricted diffusion Decrease in diameter of 10+ mm 
without treatment
Iron sparing in an iron overloaded liver
Abbreviation: HCC, hepatocellular carcinoma.
Table 4 Examples of definitely benign (category LR-1) and 
probably benign (category LR-2) lesions
Definitely benign; category 
LR-1
Probably benign; category  
LR-2
Cyst, hemangioma, focal fat 
deposition or sparing, confluent 
fibrosis, perfusion anomalies, 
focal scars, or nonhyperenhancing 
arterial nodules
Atypical presentation of cyst, 
hemangioma, focal fat deposition 
or sparing, confluent fibrosis, 
perfusion anomalies, focal scars, or 
nonhyperenhancing arterial nodules
Figure 3 HCC in a 67-year-old man with alcoholic cirrhosis.
Notes: Axial post-contrast T1-weighted MR images in arterial (A), delayed phase (B), axial T2-weighted (C), and diffusion weighted (D) MR images demonstrate an 
infiltrative mass (asterisk) with ill-defined margins, exhibiting heterogeneous enhancement in the arterial phase, washout in the delayed phase with moderately increased signal 
intensity on T2-weighted and diffusion restriction on diffusion-weighted images. There is soft tissue noted within the left portal vein (arrow) exhibiting all signal characteristics 
and contrast enhancement similar to the tumor, representing LR-5V. See Table 2 for LI-RADS classifications.
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LR-1 or LR-2, as these entities are rare in cirrhosis and, even 
when present, cannot be confidently distinguished from HCC 
in high-risk individuals.17,37,38 v2014 also does not address 
regenerative nodules occurring in the absence of cirrhosis, 
such as those associated with Budd-Chiari syndrome.17
Category LR-3
Observations in this category have an intermediate probability 
of being HCC. LR-3 includes all observations that lack both 
unequivocal major features of LR-4 and LR-5 and unequivocal 
benign features of LR-1 and LR-2.16 They do not definitively 
fit into any other LI-RADS category.17 LR-4 and LR-5 obser-
vations that are stable in size and appearance over 2 years are 
considered LR-3. The American Association for the Study 
of Liver Disease recommends that findings categorized as 
LR-3 and <10 mm be reimaged in 3–6 months. Three-month 
follow-up with contrast-enhanced CT or MRI is preferred 
over biopsy for further workup of observations >10 mm.11
Category LR-4
Observations in this category have a high probability of HCC 
and demonstrate some, but not all, major imaging features.16 
LR-4 observations are not definitely or probably benign, do 
not qualify as non-HCC malignancy, and do not include tumor 
in the vein.17 LR-4 was previously subdivided into category A 
(<20 mm) and category B (>20 mm), with one additional major 
feature required for LR-4 assignment to category A.16 This sub-
division has been discontinued in the v2014 classification since 
reporting of observation diameter is required. Probable tumor in 
vein is also considered LR-4, as any uncertainty between LR-4 
and LR-5 category assignment should be given LR-4 status.17 
As they represent probable HCC, LR-4 observations require 
close follow-up and may need additional imaging or biopsy.17
Category LR-5
Observations in this category are definitely HCC.16,17 This 
designation should be used only when imaging criteria are 
unequivocal and sufficient to render a diagnosis of HCC with 
absolute certainty without a biopsy.16 LR-5 was previously 
subdivided on the basis of size into categories A (between 
10 and 20 mm) and B (>20 mm). This subcategorization has 
now been removed in v2014.
A 10–19 mm observation requires arterial-phase hyper-
enhancement and at least two of the following major criteria: 
washout, capsule, or threshold growth, to be categorized as 
LR-5. Observations that present both washout appearance 
and visibility at antecedent surveillance ultrasound (LR-5us) 
and observations that present ≥50% diameter increase in 
≤6 months (LR-5g) are also categorized as LR-5.
Observations ≥20 mm with arterial-phase hyperenhance-
ment require at least one of the following major criteria: 
washout, capsule, or threshold growth, to be categorized 
as LR-5.
Category LR-5V
Observations with features of definite venous invasion are 
LR-5V, regardless of the presence of other major features.17
LR treated
The LR-treated category is new with the implementation 
of v2014. Any observation that has undergone locoregional 
treatment is placed into this category, regardless of whether 
or not treatment was successful.17 Residual or recurrent HCC 
may be present.17 Criteria for assessing treatment response 
are still being developed and will appear in the 2017 update.17 
Notably, observations undergoing systemic treatment are not 
classified using LR treated.17
LI-RADS and liver transplantation
In patients with cirrhosis and HCC, hepatic transplantation is 
the treatment with the highest 5-year reported survival rate of 
84% as compared to 46% and 34% for resection and ablation, 
respectively.11 The United Network for Organ Sharing gov-
erns the OPTN, which maintains a national transplant waiting 
list. The policy of these organizations is to assess mortality 
risk using the Model for End-Stage Liver Disease (MELD) 
score to assess transplant priority.22,35 Diagnosis of HCC does 
not require tissue diagnosis if OPTN class 5 imaging criteria 
for HCC are met on multiphasic post-contrast MRI or CT 
that meet minimum technical requirements.39
OPTN classification system
OPTN uses a distinct terminology for description of HCCs 
(Table 5). OPTN class 5 indicates that a nodule meets radio-
logic criteria for HCC. Class 5A refers to a single nodule 
≥1 cm and <2 cm in diameter with arterial-phase hyperen-
hancement and has at least one of two venous features of HCC 
(washout and capsule appearance). Class 5A-g (for growth) 
applies to a single nodule ≥1 cm and <2 cm in diameter with 
arterial-phase hyperenhancement and has growth by ≥50% on 
MRI or CT obtained ≤6 months apart.23,39 Class 5B applies to 
a single nodule ≥2 cm and ≤5 cm with arterial-phase hyper-
enhancement and one of the following: washout on portal 
venous or delayed phase, capsule appearance, growth by 
≥50% documented on serial MRI or CT obtained ≤6 months 
apart. Class 5T applies to class 5 lesions that were previously 
treated by locoregional ablation. Class 5X refers to lesions 
































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




Liver Imaging Reporting and Data System
Eligibility for liver transplantation
To qualify for MELD exception points, liver transplant 
candidates with HCC must have radiologic stage 2 disease 
at the time of initial prioritization, which implies either, 1) 
one HCC measuring ≥2 cm and ≤5 cm in diameter, or 2) up 
to three HCCs, each ≥1 cm and ≤3 cm in diameter.
Patients beyond Milan criteria or radiologic stage 2 dis-
ease must undergo downstaging to T2 before being consid-
ered for liver transplantation. These patients must go through 
the regional review board for determination of eligibility and 
do not receive automatic MELD exception points.
Regardless of size and number of HCCs, eligibility 
always requires absence of extrahepatic involvement and 
macrovascular invasion.11,23
LI-RADS versus OPTN
LI-RADS is used for characterization of all liver nodules 
from benign nodules to HCC, while the updated OPTN 
criteria (OPTN class 5) are used only to characterize HCC 
and determine eligibility for MELD exception points for 
the purpose of prioritization of transplant candidates with 
HCC.22,23,39 v2014 was created for congruency with OPTN-5 
criteria. Therefore, in the most updated version of LI-RADS, 
LR-5 and OPTN-5 are very similar (Table 6).16 However, 
LR-1 to LR-4 are not part of the OPTN criteria.17
LI-RADS version 2017
It is anticipated that LI-RADS will be updated in 2017 and 
2020 through the ACR. Each future iteration will incorporate 
Table 5 OPTN classification system for nodules seen on images of cirrhotic livers
Class and description Comment
OPTN class 0: incomplete or technically inadequate study Repeat study required for adequate assessment; automatic MELD priority points 
cannot be assigned on basis of an imaging study categorized as OPTN class 0
OPTN class 5: meets radiologic criteria for HCC May qualify for automatic exception depending on stage
OPTN class 5A: lesion ≥1 cm, <2 cm measured in late 
arterial or portal venous phase images
Increased arterial enhancement during the late hepatic arterial phase and washout 
during the later phases of contrast enhancement and peripheral rim enhancement 
(capsule or pseudocapsule)
OPTN class 5A-g: same size as OPTN class 5A HCC Increased contrast enhancement in the late hepatic arterial phase and growth by ≥50% 
documented on serial CT or MR images obtained ≤6 months apart
OPTN class 5B: maximum diameter ≥2 cm and ≤5 cm Increased contrast enhancement in the late hepatic arterial phase and either 
washout during later contrast phases or peripheral rim enhancement (capsule or 
pseudocapsule), 50% growth or more documented on serial CT or MR images 
obtained 6 months apart (OPTN class 5B-g)
OPTN class 5T: prior regional treatment for HCC Any residual lesion or perfusion defect at site of prior UNOS class 5 lesion
OPTN class 5X: maximum diameter ≥5 cm Increased contrast enhancement in the late hepatic arterial phase and either washout 
during later contrast phases or peripheral rim enhancement (capsule or pseudocapsule)
Notes: Data from OPTN/UNOS Liver and Intestinal Organ Transplantation Committee. Report to the Board of Directors; 2016. Available from: http://optn.transplant.hrsa.
gov.37 Reproduced, with permission, from Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J. New OPTN/UNOS policy for liver transplantation allocation: 
standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology. 2013;266(2):376–382.23
Abbreviations: HCC, hepatocellular carcinoma; CT, computed tomography; MR, magnetic resonance; UNOS, United Network for Organ Sharing; OPTN, Organ 
Procurement and Transplantation Network; MELD, Model for End-Stage Liver Disease.
Table 6 Comparison of OPTN class 5 and LI-RADS category 5
Size OPTN classification LI-RADS category
1–2 cm HCC OPTN class 5A: ≥1 cm, <2 cm measured in late arterial or portal venous 
phase images. Increased arterial enhancement during the late hepatic arterial 
phase and washout during the later phases of contrast enhancement and 
peripheral rim enhancement (capsule or pseudocapsule).
OPTN class 5A-g: increased contrast enhancement in the late hepatic 
arterial phase and growth by ≥50% documented on serial CT or MR images 
obtained ≤6 months apart.
LR-5: 10–19 mm mass with arterial-phase 
hyperenhancement and ≥2 of the following: washout 
appearance, capsule appearance, or threshold growth. 
≥2 cm HCC OPTN class B: increased contrast enhancement in late hepatic arterial 
phase and either washout during later contrast phases or peripheral rim 
enhancement (capsule or pseudocapsule).
LR-5: ≥20 mm mass with arterial-phase 
hyperenhancement and ≥1 of the following: washout 
appearance, capsule appearance, or threshold growth.
HCC with 
tumor in vein
Imaging not provided as patients with tumor in vein are not eligible for liver 
transplant.
LR-5V: HCC with tumor in vein; definite enhancing 
tissue in vein.
Notes: See Table 2 for LI-RADS classification and Table 5 for OPTN classification system for nodules seen on images of cirrhotic livers. Data from OPTN/UNOS Liver and 
Intestinal Organ Transplantation Committee. Report to the Board of Directors; 2016. Available from: http://optn.transplant.hrsa.gov37 and Wald et al.23
Abbreviations: LI-RADS, Liver Imaging Reporting and Data System; HCC, hepatocellular carcinoma; CT, computed tomography; MR, magnetic resonance; OPTN, Organ 
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new published evidence as well as patient outcomes in order 
to improve upon the existing system. In 2017, some of the 
important expansions include development of LI-RADS 
characterization of findings on ultrasound screening studies. 
Contrast-enhanced ultrasound will also be incorporated into 
LI-RADS for characterizing visible lesions identified with this 
type of cross-sectional imaging modality. There is a working 
group within LI-RADS that is helping to incorporate hepato-
biliary phase agents into interpretation of liver observations. 
An expansion of evaluation of LR-treated lesions will also 
be provided, including how to interpret findings and report 
tumors after locoregional therapy. New refinements of ancillary 
categories will be provided, in a user-friendly format, based on 
incorporation of published data as well as outcomes of consen-
sus meetings, which continue to include radiologists, hepatolo-
gists, hepatobiliary surgeons, and interventional radiologists. 
Improved standardization of image quality will be included as 
well as guidelines of how to categorize observations in the liver 
when imaging quality is suboptimal for technical or patient-
related reasons. The LI-RADS community continues to liaise 
with OPTN and AASLD in order to ensure that radiologists are 
able to provide value-added reports, which will help surgeons 
and clinicians efficiently and effectively serve their patients.
Conclusion
LI-RADS system, first created in 2011, is a consensus ACR-
supported initiative analogous to BI-RADS in breast imaging. 
LI-RADS has helped to increase clarity, consistency, and 
quality of diagnostic reports and thereby improved patient 
care. LI-RADS is a dynamic process, which is updated about 
every 3 years as imaging techniques improve, current content 
ambiguities are resolved, and user feedback is collected. 
Various components of v2014 were described in this article. 
LI-RADS will be updated in 2017 through the ACR and 
each future iteration will incorporate new evidence related 
to radiological knowledge and patient outcomes in order to 
improve upon the existing system.
Disclosure
The authors report no conflicts of interest in this work.
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